Need to get familiar with the remote patient monitoring market?

Remote patient monitoring is growing up. Medicare still pays for it, but it wants more proof that patients actually get better.

We've found a lot of interesting signals. For example, in late October 2025, Medicare finalized two new billing codes, so practices can get paid for as few as 2 days of readings in a month, or 10 minutes of a clinician's time, instead of the 16 days and 20 minutes required before. Then in December, Medicare's innovation center announced ACCESS, a ten-year program that pays for tech-supported care of conditions like high blood pressure and diabetes, and pays in full only when patients reach their health goals. Medicare is making monitoring easier to bill, and it increasingly wants to pay for results, not just readings.

In this section, we look at what these payment changes mean for monitoring companies, which conditions get paid for first, and why programs that only collect readings may struggle.

Clinics see patients a few times a year, but chronic conditions change every day, and there aren't enough nurses to call everyone.

We compare six kinds of RPM companies, from device makers and monitoring platforms to services that run whole programs for clinics. Their buyers range from small practices to health systems, home health agencies and insurers. Then we rank what hurts most, like patients who stop taking readings, alerts nobody has time to review, and billing rules that are easy to get wrong.

This shows which problems a clinic will pay to fix, and which ones only matter on a vendor's slide.

Device fees, monthly per-patient billing through Medicare codes, software licenses, revenue shares with practices and contracts that pay for results: RPM companies get paid in several ways.

We compare who pays and what each patient costs to serve. A practice that bills Medicare keeps the payment but has to staff the reviews. A turnkey service ships the device, watches the data and splits the revenue, so it carries the nurse costs. Health systems and insurers may pay for fewer hospital stays instead, which means the vendor only earns if patients do better. And every device that ends up in a drawer still has to be paid for.

You'll see which models still make money when patients drop out, and which ones depend on a billing code staying exactly as it is.

A growth rate means little until you know what drives it, so we lay the drivers out one by one.

Some are easy to see: more older patients with several chronic conditions, a shortage of nurses and doctors, and better, cheaper connected devices. Others reinforce each other. Shorter billing periods let practices start smaller programs. Payments tied to results push vendors to prove their impact. And once a health system trusts monitoring for heart failure, it tends to add blood pressure, diabetes and recovery after surgery.

Before building or investing, you should know what keeps patients taking their readings month after month, and what makes a clinic keep paying for the program.

iRhythm and Dexcom are the device names most doctors know, one for heart patches and the other for glucose sensors, but remote monitoring goes much further than two devices.

Many interesting players stay out of view. Some make the cellular hubs that carry readings from the home to the clinic. Others watch new mothers' blood pressure after birth, track fluid in heart failure patients, or run the nurse teams that call when a number looks wrong.

They're hard to compare because many sell through practices, device partners or insurers, and patients never see their name. Their results are hard to compare too: one company counts patients enrolled, another counts patients still active six months later.

Below, you'll find the market grids and ecosystem maps we've built to show who does what, from the device to the care team, and where newer companies are getting in.

Cadence, BioIntelliSense, Tenovi… a few remote monitoring companies have built real businesses, each in a very different spot.

Cadence runs monitoring programs for older patients inside more than 20 US health systems, with clinicians and AI watching the data. BioIntelliSense makes the BioButton, a wearable that tracks vital signs for weeks after a patient goes home. Tenovi sells the cellular hub and devices that other monitoring programs plug into, so it gets paid whichever platform wins. None of them has proven a model that fits every condition or every buyer.

We'll look at how these companies chose where to sit, between the device, the data and the care team, and what that teaches a startup deciding what to own.